Insider Transactions Screener
Search for and identify insider purchases or sales of company shares. The screener offers additional information and analysis on the transactions and allows users to set up alerts and receive notifications when new transactions occur.
| Ticker | Insider | Transaction Type | Ownership Type | Shares Traded | Value / Price | Filing Date |
|---|---|---|---|---|---|---|
|
MRVL
|
Mark Casper
EVP & Chief Legal Officer |
SELL
Open market or private sale
|
Direct | 7,755 Reduced 100.0% |
$954,485
$123.08 p/Share
|
Jan 17
2025 |
|
NYC
|
Nicholas S Schorsch
> 10% Shareholder |
BUY
Open market or private purchase
|
Indirect | 1,367 Added 0.0% |
$12,590
$9.21 p/Share
|
Jan 17
2025 |
|
ADAP
|
Adrian Rawcliffe
Chief Executive Officer |
SELL
Open market or private sale
|
Direct | 30,601 Reduced 40.84% |
$17,748
$0.58 p/Share
|
Jan 17
2025 |
|
ADAP
|
William C Bertrand Jr
Chief Operating Officer |
SELL
Open market or private sale
|
Direct | 5,584 Reduced 42.65% |
$3,238
$0.58 p/Share
|
Jan 17
2025 |
|
ADAP
|
John Lunger
Chief Patient Supply Officer |
SELL
Open market or private sale
|
Direct | 5,584 Reduced 42.65% |
$3,238
$0.58 p/Share
|
Jan 17
2025 |
|
ADAP
|
Elliot Norry
Chief Medical Officer |
SELL
Open market or private sale
|
Direct | 5,584 Reduced 42.65% |
$3,238
$0.58 p/Share
|
Jan 17
2025 |
|
COMP
|
Robert L. Reffkin
Chairman and CEO |
SELL
Open market or private sale
|
Direct | 42,717 Reduced 2.14% |
$294,747
$6.9 p/Share
|
Jan 17
2025 |
|
SKYH
|
Boston Omaha Corp
> 10% Shareholder |
SELL
Open market or private sale
|
Direct | 7,861 Reduced 0.07% |
$89,300
$11.36 p/Share
|
Jan 17
2025 |
|
REKR
|
David Philip Desharnais
Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct | 40,971 Reduced 3.98% |
$65,553
$1.6 p/Share
|
Jan 17
2025 |
|
BRFH
|
Lisa Roger
Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct | 1,577 Reduced 2.19% |
-
|
Jan 17
2025 |
|
MDGL
|
Shannon T Kelley
General Counsel |
SELL
Open market or private sale
|
Direct | 277 Reduced 3.47% |
$75,734
$273.41 p/Share
|
Jan 17
2025 |
|
MDGL
|
Rebecca Taub
Pres., R&D, and CMO |
SELL
Open market or private sale
|
Direct | 1,689 Reduced 0.37% |
$461,789
$273.41 p/Share
|
Jan 17
2025 |
|
MDGL
|
Robert E. Waltermire
Senior VP, Chief Pharma Dev. |
SELL
Open market or private sale
|
Direct | 442 Reduced 8.04% |
$120,847
$273.41 p/Share
|
Jan 17
2025 |
|
ONTF
|
Steven Vattuone
Chief Financial Officer |
SELL
Open market or private sale
|
Direct | 1,022 Reduced 0.19% |
$6,643
$6.5 p/Share
|
Jan 17
2025 |
|
G
|
N. V. Tyagarajan
Director |
SELL
Payment of exercise price or tax liability
|
Direct | 47,972 Reduced 6.3% |
$2,079,106
$43.34 p/Share
|
Jan 17
2025 |
|
TEM
|
Bradley A Keywell
> 10% Shareholder |
SELL
Open market or private sale
|
Indirect | 265,000 Reduced 0.0% |
$9,394,250
$35.45 p/Share
|
Jan 17
2025 |
|
BBCP
|
Iain Humphries
CFO and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct | 249,287 Added 28.15% |
$1,518,157
$6.09 p/Share
|
Jan 17
2025 |
|
BBCP
|
Iain Humphries
CFO and Secretary |
SELL
Payment of exercise price or tax liability
|
Direct | 200,920 Reduced 31.57% |
$1,766,086
$8.79 p/Share
|
Jan 17
2025 |
|
TEAM
|
Michael Cannon Brookes
CEO, Co-Founder |
SELL
Open market or private sale
|
Indirect | 7,948 Reduced 0.0% |
$2,022,686
$254.49 p/Share
|
Jan 17
2025 |
|
TEAM
|
Scott Farquhar |
SELL
Open market or private sale
|
Indirect | 7,948 Reduced 0.0% |
$2,022,686
$254.49 p/Share
|
Jan 17
2025 |
|
TEAM
|
Anutthara Bharadwaj
President |
SELL
Open market or private sale
|
Direct | 1,520 Reduced 0.72% |
$394,972
$259.85 p/Share
|
Jan 17
2025 |
|
ULCC
|
Barry Biffle
CEO |
SELL
Open market or private sale
|
Direct | 273,000 Reduced 25.05% |
$2,304,120
$8.44 p/Share
|
Jan 17
2025 |
|
ULCC
|
Barry Biffle
CEO |
BUY
Exercise of conversion of derivative security
|
Direct | 400,000 Added 24.74% |
$1,568,000
$3.92 p/Share
|
Jan 17
2025 |
|
AGBAR
|
Robert E. Diamond Jr. |
SELL
Open market or private sale
|
Indirect | 120,000 Reduced 0.0% |
$295,200
$2.46 p/Share
|
Jan 17
2025 |
|
PDEX
|
Raymond E Cabillot
Director |
SELL
Open market or private sale
|
Indirect | 6,820 Reduced 0.0% |
$305,467
$44.79 p/Share
|
Jan 17
2025 |
|
PAYX
|
B Thomas Golisano |
SELL
Bona fide gift
|
Direct | 7,145 Reduced 0.02% |
$1,056,245
$147.83 p/Share
|
Jan 17
2025 |
|
LWAY
|
Ludmila Smolyansky |
SELL
Open market or private sale
|
Indirect | 12,034 Reduced 0.0% |
$271,366
$22.55 p/Share
|
Jan 17
2025 |
|
ETD
|
M Farooq Kathwari
Chairman, President & CEO |
SELL
Open market or private sale
|
Indirect | 700 Reduced 0.0% |
$20,069
$28.67 p/Share
|
Jan 17
2025 |
|
ETD
|
M Farooq Kathwari
Chairman, President & CEO |
SELL
Open market or private sale
|
Direct | 10,000 Reduced 0.6% |
$286,700
$28.67 p/Share
|
Jan 17
2025 |
|
OPK
|
Phillip Md Et Al Frost
CEO & Chairman |
BUY
Open market or private purchase
|
Indirect | 150,000 Added 0.0% |
$220,500
$1.47 p/Share
|
Jan 17
2025 |
|
EXFY
|
David Michael Barrett
Chief Executive Officer |
SELL
Open market or private sale
|
Indirect | 32,473 Reduced 0.0% |
$110,732
$3.41 p/Share
|
Jan 17
2025 |
|
JEF
|
Brian P Friedman
President |
SELL
Bona fide gift
|
Direct | 2,500 Reduced 0.11% |
-
|
Jan 17
2025 |
|
MS
|
Andrew M Saperstein
Co-President |
BUY
Grant, award, or other acquisition
|
Direct | 51,256 Added 11.75% |
-
|
Jan 17
2025 |
|
MS
|
Andrew M Saperstein
Co-President |
SELL
Payment of exercise price or tax liability
|
Direct | 27,032 Reduced 7.02% |
$3,671,215
$135.81 p/Share
|
Jan 17
2025 |
|
MS
|
Daniel A Simkowitz
Co-President |
BUY
Grant, award, or other acquisition
|
Direct | 51,256 Added 9.31% |
-
|
Jan 17
2025 |
|
MS
|
Daniel A Simkowitz
Co-President |
SELL
Payment of exercise price or tax liability
|
Direct | 38,878 Reduced 7.79% |
$5,280,021
$135.81 p/Share
|
Jan 17
2025 |
|
MS
|
Charles Aubrey Smith Iii
Chief Risk Officer |
SELL
Payment of exercise price or tax liability
|
Direct | 20,237 Reduced 12.8% |
$2,748,386
$135.81 p/Share
|
Jan 17
2025 |
|
MS
|
Charles Aubrey Smith Iii
Chief Risk Officer |
BUY
Grant, award, or other acquisition
|
Direct | 29,328 Added 15.65% |
-
|
Jan 17
2025 |
|
MS
|
Sharon Yeshaya
Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct | 43,947 Added 22.16% |
-
|
Jan 17
2025 |
|
MS
|
Sharon Yeshaya
Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct | 13,443 Reduced 8.71% |
$1,825,693
$135.81 p/Share
|
Jan 17
2025 |
|
MS
|
Raja Akram
Deputy Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct | 23,462 Added 17.33% |
-
|
Jan 17
2025 |
|
MS
|
Raja Akram
Deputy Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct | 12,966 Reduced 11.59% |
$1,760,912
$135.81 p/Share
|
Jan 17
2025 |
|
MS
|
Mandell Crawley
Chief Client Officer |
SELL
Payment of exercise price or tax liability
|
Direct | 2,382 Reduced 3.61% |
$323,499
$135.81 p/Share
|
Jan 17
2025 |
|
MS
|
Mandell Crawley
Chief Client Officer |
BUY
Grant, award, or other acquisition
|
Direct | 22,019 Added 25.03% |
-
|
Jan 17
2025 |
|
MS
|
Eric F Grossman
Chief Legal/Admin Officer |
SELL
Payment of exercise price or tax liability
|
Direct | 22,714 Reduced 9.22% |
$3,084,788
$135.81 p/Share
|
Jan 17
2025 |
|
MS
|
Eric F Grossman
Chief Legal/Admin Officer |
BUY
Grant, award, or other acquisition
|
Direct | 43,947 Added 15.14% |
-
|
Jan 17
2025 |
|
MS
|
Michael A. Pizzi
Head Technology & Operations |
SELL
Payment of exercise price or tax liability
|
Direct | 17,855 Reduced 10.26% |
$2,424,887
$135.81 p/Share
|
Jan 17
2025 |
|
MS
|
Michael A. Pizzi
Head Technology & Operations |
BUY
Grant, award, or other acquisition
|
Direct | 29,328 Added 14.42% |
-
|
Jan 17
2025 |
|
MS
|
Edward N Pick
Chairman and CEO |
SELL
Other acquisition or disposition
|
Direct | 181,976 Reduced 22.68% |
$24,805,148
$136.31 p/Share
|
Jan 17
2025 |
|
MS
|
Edward N Pick
Chairman and CEO |
SELL
Payment of exercise price or tax liability
|
Direct | 40,052 Reduced 4.75% |
$5,439,462
$135.81 p/Share
|
Jan 17
2025 |